Aurobindo Pharma surges on USFDA nod for anti-HIV tablets
The stock rallied 6% to Rs 649 on USFDA nod for Ritonavir tablets
 "Aurobindo Pharma surges on USFDA nod for anti-HIV tablets")
Aurobindo Pharma has rallied nearly 6% to Rs 649 on the BSE on media reports that the company has received tentative approval from the United States Food and Drug Administration (USFDA) for its Ritonavir tablets which is used for treatment of human immunodeficiency virus (HIV) infection.
USFDA has given tentative approval to Aurobindo Pharma's Ritonavir tablets in the strength of 100 mg, as per the regulator. CLICK HERE TO READ FULL REPORT.
At 10:08 AM, the stock was up 5% at Rs 647 on the BSE as compared to 0.24% decline in the S&P BSE Sensex. A combined 2.69 million shares changed hands on the counter on the NSE and BSE.
USFDA has given tentative approval to Aurobindo Pharma's Ritonavir tablets in the strength of 100 mg, as per the regulator. CLICK HERE TO READ FULL REPORT.
Read more from our special coverage on "AUROBINDO PHARMA"
At 10:08 AM, the stock was up 5% at Rs 647 on the BSE as compared to 0.24% decline in the S&P BSE Sensex. A combined 2.69 million shares changed hands on the counter on the NSE and BSE.